Grown Rogue International (GRUSF) Other Non Operating Income (2010 - 2026)
Grown Rogue International (GRUSF) posted quarterly Other Non Operating Income of $165268.0 for Q1 2026, down 79.26% year-over-year from $796956.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$5714.4 billion in Q4 2025.
Grown Rogue International (GRUSF) Other Non Operating Income (2010 - 2026) Analysis & Trends
Grown Rogue International's Other Non Operating Income history runs 17 years deep, the most recent figure standing at $165268.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 79.26% year-over-year to $165268.0; the TTM figure through Mar 2026 stood at -$5738.6 billion (up 58.9% YoY), while the FY2025 annual figure was $240115.0, down 98.12% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $165268.0, up from -$5714.4 billion in the prior quarter.
- The five-year high for Other Non Operating Income was $2.9 million in Q2 2025, with the low at -$13584.8 billion in Q4 2024.
- The 5-year median for Other Non Operating Income is -$270712.0 (2023), against an average of -$1313.5 billion.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income slumped 13017363153.83% in 2024, then surged 152.48% in 2025.
- Grown Rogue International's Other Non Operating Income stood at $18487.0 in 2022, then surged by 464.5% to $104359.0 in 2023, then plunged by 13017363153.83% to -$13584.8 billion in 2024, then surged by 57.94% to -$5714.4 billion in 2025, then surged by 100.0% to $165268.0 in 2026.
- Business Quant data shows GRUSF's Other Non Operating Income at $165268.0 in Q1 2026, -$5714.4 billion in Q4 2025, and -$24.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Grown Rogue International | 113.47 Mn | 101.93 Mn | 5.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -116,128.00 |
| Mar 31, 2026 | 165,268.00 |
| Dec 31, 2025 | -5,714.40 Bn |
| Sep 30, 2025 | -24.24 Bn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 796,956.00 |
| Dec 31, 2024 | -13,584.79 Bn |
| Sep 30, 2024 | -378.59 Bn |
| Jun 30, 2024 | -5.52 Mn |
| Mar 31, 2024 | -5.66 Mn |
| Dec 31, 2023 | 104,359.00 |
| Oct 31, 2023 | 217,713.00 |
| Jul 31, 2023 | -743,682.00 |
| Apr 30, 2023 | -270,712.00 |
| Jan 31, 2023 | -64,360.00 |
| Jan 31, 2022 | 18,487.00 |
| Jul 31, 2021 | 65,543.00 |
| Apr 30, 2021 | 114,997.00 |
| Jan 31, 2021 | 319,627.00 |
| Oct 31, 2020 | 444,855.00 |